Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ SiteOne Therapeutics, Inc., a clinical-stage biopharmaceutical company developing new treatments to address conditions involving hypersensitivity of the nervous system, today announced that dosing has commenced in the company s Phase 1, dose-escalation study of ST-2427, a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain. The initiation of this study represents a significant milestone for the company as it is our first drug candidate to enter the clinic, stated John Mulcahy, Ph.D., chief executive officer of SiteOne
. There is an urgent, unmet need to develop effective non-opioid therapies for pain. Our lead compound, ST-2427, addresses that need by targeting the peripheral nerve fibers that conduct pain signals without the potential for CNS side effects, addiction and abuse liability of opioid medications.